Leyden Laboratories–SEVERAL: investment, 202103 financing round Series A €40m led by GV |
2021-03-25 |
Meatable–Agronomics: investment, 202103 financing round Series A totalling $47m incl existing investor Agronomics |
2021-03-23 |
Meatable–BlueYard Capital: investment, 202103 financing round Series A totalling $47m incl existing investor BlueYard Capital |
2021-03-23 |
Meatable–DSM: investment, 202103 financing round Series A totalling $47m incl new investor DSM Venturing |
2021-03-23 |
Meatable–Humboldt Fund: investment, 202103 financing round Series A totalling $47m incl existing investor Humboldt Fund |
2021-03-23 |
Meatable–PERSON: investment, 202103 financing round Series A totalling $47m incl existing investor Taavet Hinrikus |
2021-03-23 |
Meatable–PERSON: investment, 202103 financing round Series A totalling $47m incl new investors Rick Klausner + Jeffrey Leiden |
2021-03-23 |
Meatable–Section 32: investment, 202103 financing round Series A totalling $47m incl new investor Section 32 |
2021-03-23 |
Meatable–SEVERAL: investment, 202103 financing round Series A $47m from existing + new investors |
2021-03-23 |
Amphista Therapeutics–SEVERAL: investment, 202103 financing round Series B £38m ($53m) co-led by Forbion + Gilde Healthcare |
2021-03-17 |
ExeVir Bio–Noshaq: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Noshaq |
2021-03-16 |
ExeVir Bio–Sambrinvest: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Sambrinvest |
2021-03-16 |
ExeVir Bio–SEVERAL: investment, 202103 financing round Series A extension by €19m + closing at total of €42m |
2021-03-16 |
ExeVir Bio–UCLouvain: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Vives IUF |
2021-03-16 |
ExeVir Bio–Wallonia (govt): investment, 202103 financing round Series A extension totalling €19m incl new + co-investor SRIW |
2021-03-16 |
AgomAb Therapeutics–Advent France Biotechnology: investment, 202103 financing round Series B totalling $74m incl existing + co-investor AFB |
2021-03-10 |
AgomAb Therapeutics–Andera Partners: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Amdera Partners |
2021-03-10 |
AgomAb Therapeutics–Boehringer: investment, 202103 financing round Series B totalling $74m incl existing + co-investor BIVF |
2021-03-10 |
AgomAb Therapeutics–Cormorant Asset Management: investment, 202103 financing round Series B totalling $74m incl new + co-investor Cormorant |
2021-03-10 |
AgomAb Therapeutics–Omnes Capital: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Omnes Capital |
2021-03-10 |
AgomAb Therapeutics–Pontifax: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Pontifax |
2021-03-10 |
AgomAb Therapeutics–Redmile Group: investment, 202103 financing round Series B totalling $74m incl new + lead investor Redmile Group |
2021-03-10 |
AgomAb Therapeutics–SEVERAL: investment, 202103 financing round Series B $74m led by new investor Redmile Group |
2021-03-10 |
AgomAb Therapeutics–Trophic Communications: public relations, 202103 service existent by Trophic Communications |
2021-03-10 |
AgomAb Therapeutics–V-Bio Ventures: investment, 202103 financing round Series B totalling $74m incl existing + co-investor V-Bio Ventures |
2021-03-10 |
Diagenode–Hologic: investment, 202103 acquisition €130m of Diagenode by Hologic |
2021-03-01 |
Oxular–Forbion: investment, 202103 financing round totalling £27m incl new + lead investor Forbion |
2021-03-01 |
Oxular–SEVERAL: investment, 202103 financing round £27m led by Forbion |
2021-03-01 |
Delphi Genetics–Achelous Partners: financial services, 202102 supply service M&A adviser for sale of Delphi Genetics to Catalent |
2021-02-23 |
Delphi Genetics–Catalent: investment, 202102– acquisition 100% valuing Delphi Genetics at $55m |
2021-02-23 |
Delphi Genetics–Osborne Clarke: legal services, 202102 supply service Osborne Clarke Brussels legal adviser to Delphi Genetics on sale Catalent |
2021-02-23 |
Pan Cancer T–Netherlands (govt): grant, 202102 Health~Holland grant for public-private-partnership with Erasmus Medical Center |
2021-02-08 |
Pan Cancer T–SEVERAL: investment, 202102 seed financing round from Swanbridge Capital + Van Herk Ventures |
2021-02-08 |
Pan Cancer T–Swanbridge Capital: investment, 202102 seed financing round incl investor Swanbridge Capital |
2021-02-08 |
Pan Cancer T–Van Herk: investment, 202102 seed financing round incl investor Van Herk Ventures |
2021-02-08 |
Tecan–UgenTec: laboratory automation, 202102– collab product integration of Tecan workstations with FastFinder qPCR-s/w for sale in dx markets |
2021-02-04 |
V-Bio Ventures–SEVERAL: investment, 202102 first closing €78m capital commitments for new V-Bio Ventures Fund 2 |
2021-02-04 |
GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA |
2021-01-26 |
GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences |
2021-01-26 |
CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share |
2021-01-25 |
Neurent Medical–Life Sciences Partners: investment, 202101 financing round Series B totalling €21m incl lead investor LSP Health Economics Fund 2 |
2021-01-20 |
Neurent Medical–SEVERAL: investment, 202101 financing round Series B €21m led by LSP Health Economics Fund 2 |
2021-01-20 |
CoviCept Therapeutics–Forbion: investment, 202101 seed investment $2.3 from Forbion |
2021-01-19 |
Merus–SEVERAL: investment, 202101 public offering $120m+$18m with 4.85m+727.3k common shares at $24.75/share |
2021-01-19 |
Novasep–Thermo Fisher: investment, 202101 acquisition €725m in cash of viral vector manufacturing business Henogen SA in Belgium by Thermo Fisher |
2021-01-15 |
NewAmsterdam Pharma–SEVERAL: investment, 202101 financing round Series A €160m co-led by Morningside Ventures + Ascendant BioCapital |
2021-01-14 |
Nile AI–UCB: investment, 202101 majority investment €25m in newly launched Nile AI Inc by UCB |
2021-01-13 |
Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share |
2021-01-12 |
Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP |
2021-01-11 |
BioGeneration Ventures–BMS: investment, 202101 final closing of BGV IV totalling €140m incl investor BMS |
2021-01-07 |
BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund |
2021-01-07 |
BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital |
2021-01-07 |
BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension |
2021-01-07 |
BioGeneration Ventures–Instinctif Partners: public relations, 202101 service existent by Instinctif |
2021-01-07 |
BioGeneration Ventures–Lilly: investment, 202101 final closing of BGV IV totalling €140m incl investor Eli Lilly |
2021-01-07 |
BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures |
2021-01-07 |
BioGeneration Ventures–Schroders: investment, 202101 final closing of BGV IV totalling €140m incl investor Schroder Adveq |
2021-01-07 |
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al |
2021-01-07 |
Volta Medical–Gilde Investment: investment, 202101 financing round totalling $28m incl lead investor Gilde Healthcare |
2021-01-05 |
Volta Medical–SEVERAL: investment, 202101 financing round $28m led by Gilde Healthcare |
2021-01-05 |
Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use |
2021-01-01 |
Immunicum–Van Herk: investment, 202012c largest shareholder holding 43% after merger of Immunicum with DCprime |
2020-12-31 |
Univercells–Farallon Capital: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor Farallon Capital Management |
2020-12-17 |
Univercells–Korea Investment Partners: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor KIP Bio Global Fund |
2020-12-17 |
Univercells–SEVERAL: investment, 202012 financing round Series C 2nd closing €20m with Soros EDF + Farallon Capital et al |
2020-12-17 |
Univercells–Soros Economic Development Fund: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor Soros EDF |
2020-12-17 |
Univercells–TheClubDeal Fund: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor TheClubDeal Fund |
2020-12-17 |
Locanabio–SEVERAL: investment, 202012 financing round Series B $100m led by Vida Ventures |
2020-12-14 |
Locanabio–UCB: investment, 202012 financing round Series B incl existing + co-investor UCB Ventures |
2020-12-14 |
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED |
2020-12-01 |
Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund |
2020-11-25 |
Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG |
2020-11-25 |
Innatera Nanosystems–SEVERAL: investment, 202011 seed financing round €5m co-lead by MIG Verwaltungs AG + btov Industrial Technologies Fund |
2020-11-25 |
Galapagos–Selvita: drug discovery services, 202011– 202512 supply for 5y by Fidelta after sale by Galapgaos to Selvita |
2020-11-23 |
Galapagos–Selvita: investment, 202011– acquisition 100% of Fidelta d.o.o. for €31.2m in cash by Selvita SA |
2020-11-23 |
Achilles Therapeutics–Forbion: investment, 202011 financing round Series C totalling £52.7m incl existing investor Forbion |
2020-11-19 |
Achilles Therapeutics–SEVERAL: investment, 202011 financing round Series C £52.7m with new + existing investors |
2020-11-19 |
SynOx Therapeutics–Forbion: investment, 202011 financing round Series A totalling €37m incl co-investor Forbion |
2020-11-19 |
SynOx Therapeutics–Gimv: investment, 202011 financing round Series A totalling €37m incl co-investor Gimv |
2020-11-19 |
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv |
2020-11-19 |
BioInvent–Van Herk: investment, 202011 existent Van Herk is largest shareholder of BioInvent |
2020-11-18 |
DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED |
2020-11-18 |
Pharvaris–Bain Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Bain Capital Life Sciences |
2020-11-18 |
Pharvaris–Cormorant Asset Management: investment, 202011 financing round Series C totalling $80m incl new + co-investor Cormorant Asset Management |
2020-11-18 |
Pharvaris–Foresite Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Foresite Capital |
2020-11-18 |
Pharvaris–General Atlantic: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor General Atlantic |
2020-11-18 |
Pharvaris–Rockefeller: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Venrock Health Capital Partners |
2020-11-18 |
Pharvaris–SEVERAL: investment, 202011 financing round Series C $80m co-led by Viking Global Investors + General Atlantic |
2020-11-18 |
Pharvaris–VenBio: investment, 202011 financing round Series C totalling $80m incl existing + co-investor venBio Partners |
2020-11-18 |
Pharvaris–Viking Global Investors: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor Viking Global Investors |
2020-11-18 |
Lead Pharma–LifeSpring: public relations, 202011 service existent by LifeSpring Communications |
2020-11-16 |
Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties |
2020-11-16 |
Apaxen–LifeSpring: public relations, 202011 service existent by LifeSpring Life Sciences Communications |
2020-11-12 |
Handl Therapeutics–UCB: investment, 202011 acquisition of Handl Therapeutics by UCB |
2020-11-12 |
Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III |
2020-11-10 |
Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III |
2020-11-10 |
The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings |
2020-11-03 |
Eurofins–Waters: mass spectrometer, 202011 supply existent Radian ASAP System beta customer Eurofins Forenscis Teddington |
2020-11-02 |
Fountain Healthcare Partners–Kyowa Kirin: investment, 202011 final closing of Fund III totalling addit €7m incl new investor Kyowa Kirin Co Ltd |
2020-11-02 |